kabutan

Medrx Co.,Ltd.(4586) Summary

4586
TSE Growth
Medrx Co.,Ltd.
115
JPY
-1
(-0.86%)
Dec 12, 3:30 pm JST
0.73
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
116
Dec 12, 11:23 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.28
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
116 JPY 0.74 USD
Previous Close Dec 11
116 JPY 0.74 USD
High Dec 12, 9:05 am
121 JPY 0.77 USD
Low Dec 12, 2:50 pm
115 JPY 0.73 USD
Volume
1,085,700
Trading Value
0.13B JPY 0.82M USD
VWAP
118.24 JPY 0.76 USD
Minimum Trading Value
11,500 JPY 73 USD
Market Cap
6.83B JPY 0.04B USD
Number of Trades
443
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
844
1-Year High Sep 29, 2025
32,058
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 7,191,100
Nov 28, 2025 0 6,953,500
Nov 21, 2025 0 7,141,800
Nov 14, 2025 300 7,823,200 26077.33
Nov 7, 2025 0 7,919,100
Company Profile
Medrx Co., Ltd. is a drug discovery venture company with strengths in transdermal drug delivery system technologies and microneedle array technology.
Sector
Pharmaceuticals
Medrx Co., Ltd. aims to create new value-added pharmaceuticals through its proprietary transdermal drug delivery system technologies, primarily ILTS and NCTS. These technologies maximize drug efficacy, reduce side effects, and enable drug administration to patients who have difficulty with oral intake. One of the company's main development pipelines, MRX-5LBT for the treatment of post-herpetic neuralgia, received a Complete Response Letter from the FDA in September 2023. Other pipelines include MRX-4TZT for spastic paralysis, MRX-9FLT for central analgesic, and MRX-7MLL for Alzheimer's disease. Additionally, the company is developing microneedle technology, a vaccine delivery device that allows for painless self-administration. Medrx Co., Ltd. is expanding globally through its U.S. subsidiary and is promoting development and commercialization through partnerships with pharmaceutical companies and other entities.